CycloME part B

Part B of the CycloME trial includes patients with severe to very severe CFS/ME.

Based on an analysis of the preliminary response and toxicity data from CycloME, part A, we concluded that in order to extend the trial to include patients with severe to very severe ME, we needed to adjust the protocol and plan the intervention and follow-up of each patient with great care. In order to gain more experience with this highly vulnerable group of patients, we received approval from the Regional Ethics’ committee and the Norwegian Medicines Agency to conduct a small pilot study. Treatment and follow-up in the pilot study have now been completed.

ME/CFS research


​​Did you find what you were looking for?